摘要
目的观察和探讨替格瑞洛治疗急性冠状动脉综合征的临床疗效。方法选择烟台山医院2015年4月—2016年3月经皮冠状动脉介入术治疗的ACS患者37例随机分为两组,观察组19例口服替格瑞洛,对照组18例口服氯吡格雷,观察两组患者手术前及术后24 h血小板抑制率、肌红蛋白、血肌酐、心肌肌钙蛋白、肌酸激酶同工酶-MB水平。结果术后观察组患者血小板抑制率为(76.2±7.9)%,肌红蛋白水平(16.2±3.6)μg/L、血肌酐水平(117.8±19.5)μmol/L,与对照组相比差异有统计学意义(P<0.05);心肌肌钙蛋白水平和肌酸激酶同工酶-MB水平与对照组比较差异无统计学意义(P>0.05)。结论经皮冠状动脉介入术治疗同时应用替格瑞洛抗血小板聚集、缓解心肌损伤作用较氯吡格雷更为显著。
Objective To observe and explore the clinical effect of ticagrelor in the treatment of acute coronary syn- drome. Methods Choose from April 2015 to March 2016 percutaneous coronary interention period treatment of 37 pa- tients from Yantaishan Hospital with ACS were randomly divided into two groups, in which observation group:19 cases of treated with oral ticagrelor,and control group of 18 cases treated withclopidogrel. Surgery patients were observed be- fore and after 24 h platelet inhibition rate, myoglobin, creatinine, cardiac troponin, creatine kinase-MB levels. Results The platelet inhibition rate (76.2±7.9)%, myoglobin levels (16.2±3.6)μg/L, serum creatininc level (117.8±19.5)μmol/L, compared with the control group, the difference was significant(P〈0.05);while in cardiac troponin levels and creatine kinase-MB levels ,there is no significant difference (P〉0.05). Conclusion Percutaneous coronary intervention therapy while application with ticagrelor anti-platelet aggregation, relieve myocardial injury, compared with clopidogrel is more significant.
作者
李江华
刘万卉
LI Jiang-hua LIU Wan-hui(Pharmaceutical School, Yantai Univercity , Yantai ,Shandong Province, 264000 Chin)
出处
《系统医学》
2017年第2期121-123,共3页
Systems Medicine